AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
|Videos|April 19, 2023
Leveraging Clinical Opportunities For Success
Dean Koskinas, PharmD, is the Execute Sales Consultant at Transaction Data Systems. He joined the Spring 2023 TPSS to discuss the best ways to integrate technology into all aspects of a pharmacy.
Advertisement
Pharmacies face various barriers in regard to medication adherence and intervention. In his seminar "Beyond The Counter: Leveraging Clinical Opportunities For Success" Dean Koskinas, PharmD from Transaction Data Systems discusses how to utilize the community pharmacist in an attempt to improve health outcomes.
Spring 2023: Expansion of Services Within Independent Pharmacy
Advertisement
Related to this article
Harini Bupathi, Esq, joins to discuss the impacts of PBM network terminations and how pharmacies can recover financially.
AJ Barbarito, Esq, provides nuance to the evolving pharmacy reimbursement landscape and how PBMs and pharmacies alike are adapting as they approach 2027.
Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.
Lara Zakaria, PharmD, MS, CNS, FMCP, illustrates the breadth of health technology going in and out of community pharmacy practice.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Matt Martin, PharmD, BCSCP, explores current developments in the peptide space and what pharmacists need to know amid FDA decision-making processes.
In celebration of American Pharmacists Month, Melissa McGivney, PharmD, FAPhA, FCCP, provides a snapshot of where the profession has come and where it still has to go.
Advertisement
Advertisement
Trending on Drug Topics
1
CagriSema Reduces Weight in Women Across Menopause Stages, HT Use
2
EloraTZP Shows Greater Weight Loss, A1C Reduction Than Tirzepatide
3
Future IRA Drug Negotiations Expected to Compound Pharmacy Burden
4
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
5